Abstract:Abstract High-parameter flow cytometry provides a powerful tool for in-depth analysis of CAR T cell therapy, from characterizing CAR T cell populations to understanding their interactions within the tumor microenvironment. This information is crucial for advancing CAR T cell therapies and improving their effectiveness in treating cancer. To address the need for deep immunoprofiling at all stages of CAR T cell therapy, we created a robust and comprehensive mass cytometry panel of antibodies against 44 cell surface and intracellular markers. This assay allows for comprehensive characterization of CAR T cell features including surface marker expression, activation state, cytokine production, and differentiation status. These data will provide researchers with a better understanding of the phenotype of the CAR T cells used in therapy and can guide optimization efforts to enhance expansion, persistence, and self-renewal. For example, newer-generation CAR T cells (T cells redirected for antigen-unrestricted cytokine-initiated killing, or TRUCKs) that are engineered to produce cytokines such as IL-2 to enhance their own survival can be evaluated in vitro to select CAR constructs with the most potent anti-tumor activity. The lyophilized and validated 30-marker Maxpar® DirectTM Immune Profiling AssayTM enables comprehensive characterization of immune cell populations in both whole blood and PBMC. The 7-marker Maxpar Direct T Cell Expansion Panel 3 (OX40, TIGIT, CD69, PD-1, Tim-3, ICOS, and 4-1BB) and the Maxpar Direct Basic Activation Expansion Panel (CD107a, IL-2, TNFα, IFNγ, perforin, and granzyme B) are add-on modules that can further characterize CAR T cell exhaustion, degranulation, cytokine production, and cytotoxicity against target cells. We also compared CAR T detection options for sensitivity and specificity using a CD19 CAR-transduced cell line spiked into healthy donor PBMC. Indirect staining with Miltenyi Biotec biotinylated CD19 CAR Detection Reagent followed by anti-biotin- or streptavidin-conjugated metal tags was compared against a directly conjugated or biotinylated anti-G4S linker antibody. We included sample multiplexing using 6 metal-tagged CD45 antibodies to address the need to minimize batch effects, crucial to multi-site and longitudinal studies. Samples were acquired on a CyTOF® XTTM instrument, and preliminary data analysis was performed using Maxpar PathsetterTM for automated enumeration of immune cells. By combining the lyophilized single-tube Maxpar Immune Profiling Assay and Expansion Panels with specific detection of CAR T cells, this assay enables researchers to analyze multiple key parameters simultaneously at the single-cell level at all stages of CAR T therapy development. For Research Use Only. Not for use in diagnostic procedures. Citation Format: Deeqa Mahamed, Geneve Awong, Thiru Selvanatham. A high-parameter mass cytometry panel for the functional characterization of CAR T cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6333.

High‐Throughput Single‐Cell Microarray Platform for CAR‐T in Vitro Systemic Immunotherapy Function Evaluation (1/2024)

Immune function assessing of TIM3/CD28‐modified CD19 CAR‐T cells and general CD19 CAR‐T cells through a high‐throughput single‐cell microarray platform

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response

3D live imaging and phenotyping of CAR-T cell mediated-cytotoxicity using high-throughput Bessel oblique plane microscopy

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines

High-multiplex Single-Cell Imaging Analysis Reveals Tumor Immune Contexture Associated with Clinical Outcomes after CAR T-cell Therapy

Assessment of Chimeric Antigen Receptor T Cytotoxicity by Droplet Microfluidics in Vitro

High‐Throughput Image Cytometry Detection Method for CAR‐T Transduction, Cell Proliferation, and Cytotoxicity Assays

3D live imaging and phenotyping of the subcellular cytotoxicity in cancer immunotherapy using event-triggered Bessel oblique plane microscopy

Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor

An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells

Assessment of CAR-T Cell-Mediated Cytotoxicity in 3D Microfluidic Cancer Co-Culture Models for Combination Therapy

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells

Abstract 6333: A high-parameter mass cytometry panel for the functional characterization of CAR T cells

A Real-Time Potency Assay For Chimeric Antigen Receptor T Cells Targeting Solid And Hematological Cancer Cells

Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors

Optimizing ex vivo CAR-T cell-mediated cytotoxicity assay through multimodality imaging

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity

Chimeric antigen receptor-T cell efficacy can be evaluated on an Organ-Chip model system